EN DE

CareRx Corporation (CRRX) Fair Value & Analysis

Healthcare · CA · Market cap C$213M

CC CareRx Corporation CRRX · TO
PriceC$3.37
Fair ValueC$6.29
Upside+86.7%
Quality44/100
Watch CareRx Corporation for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 7.2% net margin
Low debt · generates free cash flow
1.78% dividend yield
Ranks above peers (9/15)
Moderate moat 51/100
Evidence: High Range C$3.57 – C$8.75 Share as image

Fair value as of: Jul 17, 2026

From 26 valuation models · updated 24 days ago

Fair value updated Jul 17, 2026, revised from C$6.26 to C$6.29 (+0.5%) since Jul 15, 2026. Share price −4.0% over the past month.

Below-average quality, screening 87% undervalued on our models.

What matters now

  • The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain.
  • The price is below even our cautious bear case (C$3.57). The market is more pessimistic than our downside scenario.
  • A fairly wide model range (C$3.57 to C$8.75) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

C$6.79 C$1.12 Fair Value C$6.29 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range C$1.12 – C$6.79 · fair‑value band C$3.57 – C$8.75 · the C$3.37 price screens below the C$6.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CareRx Corporation (CRRX) currently trades at C$3.37, while our model-based Fair Value estimate is C$6.29, implying the stock looks roughly 86.7% undervalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, CareRx Corporation generated revenue of C$375M at a net margin of 7.2%. Revenue grew 4.9% year over year. It earns a return on equity of 27.5%. Net debt stands at C$63.5M. Fundamentals as of Jul 17, 2026

Our scenario range runs from C$3.57 (bear case) to C$8.75 (bull case); at C$3.37, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 87%, CRRX screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF C$2.84 C$4.51 C$6.75 80
Residual Income C$2.17 C$3.12 C$14.89 76
Rev-Margin DCF C$1.96 C$3.25 C$4.94 74
All 26 models by family
DCF Models
FCF DCF C$2.90 C$4.85 C$7.68 38
Owner Earnings C$5.40 C$8.86 C$13.86 31
5Y Revenue Exit C$1.96 C$3.25 C$4.93 39
5Y EBITDA Exit C$3.66 C$6.78 C$10.69 41
5Y P/E Exit C$4.63 C$8.78 C$13.55 38
10Y Revenue Exit C$2.26 C$3.51 C$5.31 36
10Y EBITDA Exit C$3.28 C$5.73 C$9.44 37
10Y P/E Exit C$3.83 C$6.98 C$11.49 35
Earnings-Based
Graham-Dodd C$2.80 C$13.21 C$18.16 54
Lynch FV C$3.50 C$5.00 C$6.50 50
PEG = 1.0 C$3.50 C$5.00 C$6.50 46
EPV C$0.8600 C$1.01 C$1.13 59
Dividend Discount
Gordon GGM C$0.1400 C$0.2300 C$0.3000 70
DDM Multi-Stage C$0.1400 C$0.2200 C$0.2500 61
Multiples
P/E Multiple C$6.79 C$9.06 C$11.32 63
P/S Multiple C$5.25 C$7.00 C$8.75 58
P/B Multiple C$5.25 C$7.00 C$8.75 55
EV/EBIT C$2.05 C$2.84 C$3.64 53
EV/EBITDA C$4.66 C$6.33 C$7.99 54
EV/Revenue C$1.36 C$2.09 C$2.83 43
Asset-Based
NCAV (Graham) C$0.8600 C$1.16 C$1.73 50
Growth DCF
Growth DCF C$2.84 C$4.51 C$6.75 80
Rev-Margin DCF C$1.96 C$3.25 C$4.94 74
Economic Profit
Residual Income C$2.17 C$3.12 C$14.89 76
ROIC Compounder C$0.8600 C$1.01 C$1.13 72
Growth Earnings
Growth-Adj P/E C$5.67 C$8.11 C$10.54 68

Widest divergence: Growth Earnings (C$8.11) versus Dividend Discount (C$0.2200). Highest evidence: Growth DCF (80).

Notify me when CRRX reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) C$375M
Revenue growth (YoY) +4.9%
Net margin 7.2%
Return on equity 27.5%
Free cash flow C$22.0M FY2025
P/E ratio 7.8
More key figures
Operating margin 3.7%
EPS (TTM) C$0.4300
Dividend yield 1.8%
EPS growth (YoY) +426%
Net debt C$63.5M FY2025

Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 44/100

Of which business quality 44 · Market factors (momentum, volatility) 56

Profitability 70
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 34
Balance sheet, leverage, solvency risk
Investment 68
Disciplined investing over empire-building
Low Volatility 78
Calm price path (market factor)
Momentum 41
Price trend over the last 3–12 months (market factor)
52W Momentum 56
Distance to the 52-week high (market factor)
Net Issuance 5
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

CareRx Corporation, together with its subsidiaries, provides pharmacy services to senior homes and other congregate care settings in Canada. The company also offers medication management services. It serves long-term care homes, retirement homes, assisted living facilities, and group homes.

Full company description

CareRx Corporation, together with its subsidiaries, provides pharmacy services to senior homes and other congregate care settings in Canada. The company also offers medication management services. It serves long-term care homes, retirement homes, assisted living facilities, and group homes. The company was formerly known as Centric Health Corporation and changed its name to CareRx Corporation in June 2020. CareRx Corporation was incorporated in 2001 and is based in Toronto, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

CareRx Corporation reported revenue of C$370M in FY2025 versus C$263M in FY2021, a compound +9.0%/yr. Reported net income was C$26.1M in FY2025.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
C$370M
Latest YoY
+1.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.0%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+17.9%
Avg. growth/yr (22Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.9%
Revenue +9.0%/yr
FY21 C$263M
FY22 C$382M
FY23 C$371M
FY24 C$367M
FY25 C$370M
Net income
FY21 −C$22.7M
FY22 −C$34.4M
FY23 −C$5.4M
FY24 −C$4.5M
FY25 C$26.1M

Watch CRRX: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "CareRx Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CRRX

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 44 · Bottom 25%
Fair Value upside +87% · Top 25%
Return on equity (TTM) 28% · Top 25%
Return on assets 3% · Below median
Net margin (TTM) 7% · Above median
Operating margin (TTM) 4% · Below median
Revenue growth 5% · Above median
Dividend yield (TTM) 1.8% · Below median
Debt / equity 0.33× · Higher than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 7.8× · Cheaper than 75% of peers
P/B 1.39× · Cheaper than median
P/S (TTM) 0.41× · Cheaper than 75% of peers
P/FCF 6.9× · Pricier than median
EV/EBITDA 6.9× · Cheaper than median
PEG 0.08× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 23
FUTURE 25 · sector 24
PAST 100 · sector 30
HEALTH 84 · sector 90
DIVIDEND 36 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare CareRx Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is CareRx Corporation (CRRX) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of C$6.29 versus a price of C$3.37, about +87% (undervalued).
What is the fair value of CRRX?
Our model-based fair value for CareRx Corporation is C$6.29 (as of Jul 17, 2026), built from audited fundamentals. The current price is C$3.37.
What is the quality score of CRRX?
CareRx Corporation has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of CareRx Corporation (CRRX)?
CareRx Corporation reported trailing-twelve-month revenue of about C$375M (latest available figure, as of Jul 17, 2026).
What is the net profit margin of CRRX?
The net profit margin of CareRx Corporation is about 7.2%, meaning it keeps roughly 7.2% of revenue as net income. Based on the latest reported figures.
Does CareRx Corporation pay a dividend?
CareRx Corporation currently shows a dividend yield of about 1.86% relative to its recent price (as of Jul 17, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track CareRx Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.